ELAN Stock Analysis — Elanco Animal Health
Sector: Healthcare
AI Verdict
You're paying a small premium for above-average growth, but the moat is real—if Elanco can keep up its 10.5% growth, the numbers look fair.
Competitive Moat
Elanco develops and manufactures veterinary medicines and vaccines for both pets and livestock, benefiting from regulatory barriers and entrenched relationships with veterinarians and large agricultural producers. Its defensibility comes from a broad product portfolio and high switching costs for customers reliant on consistent animal health outcomes.
Summary
Elanco is drawing attention for its 10.5% revenue growth as it trades below the sector median on forward earnings.
Where It Stands
Elanco trades at 23.1x next year's earnings versus the healthcare sector median of 22x, while posting 10.5% revenue growth year-over-year.
Key Metrics
- Forward P/E: 23.1x
- Revenue Growth: +0.1%
- 52-Week High: $27.72
- 52-Week Low: $13.39
Analyst Consensus
20 Buy · 2 Hold · 0 Sell (22 analysts)
Bull Case
A 10.5% revenue growth rate supports paying a slight premium to the sector's 22x median forward P/E, especially given Elanco's entrenched customer base.
Bear Case
At 23.1x forward earnings, any disappointment in growth or margin expansion could push the stock down to the sector median, implying a potential 5%–7% downside from multiple compression alone.
Catalyst to Watch
Upcoming product launches or regulatory approvals could accelerate growth and justify the current valuation premium.